Haemocytometric profile and plasma levels of selected cytokines in patients at various stages of cervical cancer

• Authors: Mutiu Alani Jimoh , Abdulfatah Adekunle Onifade , Fayeofori Mpakaboari Abbiyesuku , Victory Fabian Edem , Sheu Kadiri Rahamon , Olatunbosun Ganiyu Arinola

Abstracts

EN

Introduction and aim. Reports have shown that there is alteration in haematological and inflammatory processes in patients with cervical cancer. However, there is the dearth of information on the pattern of alteration in Nigerian patients with cervical cancer at various stages of the disease. Therefore, haemocytometric profile and plasma levels of interleukin-6 (IL-6) and IL-12 were determined in Nigerian patients with cervical cancer at various stages of the disease. Material and methods. Eighty-nine adults consisting of 49 patients with cervical cancer and 40 apparently healthy controls were enrolled into this study. Haemocytometric profile was determined using automated haematology analyzer while the plasma levels of interleukin-6 (IL-6) and IL-12 were determined using ELISA. Results. Of the participants with cervical cancer, 6.12%, 24.49%, 53.06% and 16.33% were in stages I, II, III and IV respectively. The mean plasma IL-6 level was significantly higher in patients at stage IV of the cancer compared with those in stages I, II and III. No significant differences were observed in the mean plasma IL-12 level, and the haemocytometric profile when patients in different stages of the cancer were compared with one another. Plasma IL-6 had significant positive correlation with the lymphocytes count and cancer stage but had significant negative correlation with packed cell volume (PCV), haemoglobin and total white blood cells count (WBC) in patients with cervical cancer. Conclusion. Interleukin-6 appears to play an important role in the progression of cervical cancer and could be involved in cervical cancer-associated alteration in haemocytometric profile.

Keywords

EN

cancer stage; cervical cancer; haemocytometry; interleukin-6; parity

• Publisher: Uniwersytet Rzeszowski. Wydawnictwo Uniwersytetu Rzeszowskiego
• Journal: European Journal of Clinical and Experimental Medicine
• Year: 2023
• Issue: 4
• Pages: 696-703

Dates

published

2023

Contributors

author

Mutiu Alani Jimoh

• Department of Radiation Oncology, College of Medicine, University of Ibadan, Ibadan, Nigeria

author

Abdulfatah Adekunle Onifade

• Department of Immunology, College of Medicine, University of Ibadan, Ibadan, Nigeria

author

Fayeofori Mpakaboari Abbiyesuku

• Department of Chemical Pathology, Babcock University, Illishan-Remo, Ogun State, Nigeria

author

Victory Fabian Edem

• Department of Immunology, College of Medicine, University of Ibadan, Ibadan, Nigeria

author

Sheu Kadiri Rahamon

• Department of Immunology, College of Medicine, University of Ibadan, Ibadan, Nigeria

author

Olatunbosun Ganiyu Arinola

• Department of Immunology, College of Medicine, University of Ibadan, Ibadan, Nigeria

Identifiers

DOI

10.15584/ejcem.2023.4.2

Biblioteka Nauki

29520454